SLC1A5 and nonpapillary renal cell carcinoma: Our data are consistent with these studies as well as with metabonomic studies of ccRCC that enhanced glutamine metabolism was related to sunitinib resistance, with the glutamine transporter SLC1A5 being significantly overexpressed in sunitinib-resistant samples compared to the control group [32].